Cancer medicine, Lartruvo (olaratumab), does not prolong life
Last updated: 01 November 2019
In a recent phase 3 clinical trial, Lartruvo (olaratumab)’s manufacturer stated that the medicine failed to confirm its clinical benefit in combination with a chemotherapy medication for patients with advanced or metastatic soft tissue sarcoma (STS). There were no significant differences between combining Lartruvo (olaratumab) with chemotherapy or treating patients with chemotherapy on its own. Click here for more information.
In the meanwhile, the European Medicines Agency (EMA) and US Food and Drug Agency (FDA) have issued press releases with information for patients with advanced or metastatic STS:
- New patients should not begin treatment with the medicine.
- Patients currently taking Lartruvo (olaratumab) should consult their doctor to see whether they should continue treatment with the medicine.
- There are no new safety concerns with the medicine.